Priming the translational pipeline for hemostasis therapies

ISTH Academy, James Morrissey, 393983

The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF–FVIII clearance in thrombosis and hemostasis

ISTH Academy, David Lillicrap, 393984

Thromboinflammation in long COVID—the elusive key to postinfection sequelae?

ISTH Academy, Faculty / Presenters, 393985

Standardization of extracellular vesicle concentration measurements by flow cytometry: the past, present, and future

ISTH Academy, Faculty / Presenters, 393986

Coagulopathy of liver disease—a pathophysiologic rebalance of hemostasis and thrombosis

ISTH Academy, Alvin Schmaier, 393987

Surviving a sticky situation: therapeutic administration of fibrinogen variant γ’ improves outcomes of Staphylococcus aureus septicemia

ISTH Academy, , 393988

Another layer of complexity in ectodomain shedding of platelet glycoprotein Ibα

ISTH Academy, Renhao Li, 393989

Sulfenylation: an emerging element of the protein disulfide isomerase code for thrombosis

ISTH Academy, , 393990

Long-term outcome of chronic thromboembolic pulmonary hypertension in the era where direct oral anticoagulants become available

ISTH Academy, Shinya Goto, 393991

A commentary on “Thromboinflammation in long COVID – the elusive key to post-infection sequelae?”

ISTH Academy, Faculty / Presenters, 393992

Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays

ISTH Academy, Faculty / Presenters, 393993

In vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation

ISTH Academy, Ton Lisman, 393994

Disulfide bond reduction and exchange in C4 domain of von Willebrand factor undermines platelet binding

ISTH Academy, , 393995

Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice

ISTH Academy, Denise Sabatino, 393996

Sonorheometry versus rotational thromboelastometry in trauma: a comparison of diagnostic and prognostic performance

ISTH Academy, Faculty / Presenters, 393997

Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study

ISTH Academy, Alessandro Casini, 393998

Sulfenylation links oxidative stress to protein disulfide isomerase oxidase activity and thrombus formation

ISTH Academy, Robert Flaumenhaft, 393999

Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study

ISTH Academy, Faculty / Presenters, 394000

Mitochondrial calcium uniporter b deletion inhibits platelet function and reduces susceptibility to arterial thrombosis

ISTH Academy, Anil Chauhan, 394001

Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH

ISTH Academy, Faculty / Presenters, 394012

HTRS2023.O6A.1 Leveraging quantitative platelet adhesion and platelet geometry-sensing assays to evaluate platelet function in type 1 von Willebrand disease

ISTH Academy, Faculty / Presenters, 401373

HTRS2023.O6A.2 Mobile application measurement of menstrual cycle characteristics and its association with dysmenorrhea and activity limitation in early adolescents

ISTH Academy, Faculty / Presenters, 401374

HTRS2023.O6A.3 Identification of major bleeding depends on the definition: an analysis of the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database

ISTH Academy, Faculty / Presenters, 401375

HTRS2023.O6A.4 Proteomic analysis reveals proteins that are differently expressed in factor XI-deficient non-bleeders and bleeders

ISTH Academy, Faculty / Presenters, 401376

HTRS2023.O6B.1 Interaction of antithrombin with vascular GAGs is required for its anti-inflammatory signaling but not anticoagulant protease-inhibitory function

ISTH Academy, Faculty / Presenters, 401377

HTRS2023.O6B.2 Allosteric regulation of coagulation factor IXa

ISTH Academy, Faculty / Presenters, 401378

HTRS2023.O6B.3 FVIII deficiency leads to lower atherogenic ApoB-lipoprotein and higher fibrinolysis

ISTH Academy, Faculty / Presenters, 401379

HTRS2023.O6B.4 FXIII-mediated cross-linking of hepatic fibrin is a critical driver of platelet accumulation and liver regeneration after partial hepatectomy

ISTH Academy, Faculty / Presenters, 401380

HTRS2023.O8A.1 Plasmic (PLASMICkid) score for pediatric thrombotic thrombocytopenic purpura

ISTH Academy, Faculty / Presenters, 401381

HTRS2023.O8A.2 Exercise capacity is reduced in children and adolescents following pulmonary embolism

ISTH Academy, Faculty / Presenters, 401382

HTRS2023.O8A.3 Bringing PERT to pediatrics: implementing and examining outcomes of the first pediatric Pulmonary Embolism Response Team (PERT)

ISTH Academy, Faculty / Presenters, 401383

HTRS2023.O8A.4 Proton pump inhibitors are an additive risk factor for hormonal contraception related thrombosis

ISTH Academy, Faculty / Presenters, 401384

HTRS2023.O8B.1 HIF-1 inhibition attenuates venous thrombosis in JAK2V617F transgenic mice

ISTH Academy, Faculty / Presenters, 401385

HTRS2023.O8B.2 Proteome and phosphoproteome analyses of SARS-CoV-2 infected humanized ACE2 mice platelets reveal early hyperactive and late antiviral phenotypes

ISTH Academy, Faculty / Presenters, 401386

HTRS2023.O8B.3 Elucidating the molecular mechanism of excessive phosphatidylserine exposure in sickle red cells

ISTH Academy, Faculty / Presenters, 401387

HTRS2023.O8B.4 Fatty acid oxidation fuels agonist-induced platelet activation and thrombus formation: targeting beta-oxidation of fatty acids as an effective anti-platelet strategy

ISTH Academy, Faculty / Presenters, 401388

HTRS2023.O8C.1 Subcutaneous concizumab prophylaxis in patients with hemophilia A or B with inhibitors: efficacy, safety, and physical activity score, primary analysis from the phase 3 explorer7 trial

ISTH Academy, Faculty / Presenters, 401389

HTRS2023.P2.6 Burden of disease and impact on quality of life in hereditary factor X deficiency patients who have experienced menorrhagia: findings from the Hereditary Factor X Deficiency in America survey

ISTH Academy, Faculty / Presenters, 401401

HTRS2023.P2.7 Burden of disease and impact on quality of life in hereditary factor X deficiency patients receiving prophylaxis: findings from the Hereditary Factor X Deficiency in America survey

ISTH Academy, Faculty / Presenters, 401402

HTRS2023.P2.9 Fitusiran prophylaxis demonstrates sustained bleed protection in people with hemophilia A or B: an exploratory analysis of antithrombin levels and peak thrombin generation from three phase 3 trials

ISTH Academy, Faculty / Presenters, 401403

HTRS2023.P2.10 Structured assessments and clinical phenotypes in bleeding of unknown cause

ISTH Academy, Faculty / Presenters, 401404

HTRS2023.P2.11 Personalized prophylaxis with simoctocog alfa in adult Japanese previously treated patients with severe hemophilia A

ISTH Academy, Faculty / Presenters, 401405

HTRS2023.P2.12 Reactivation of factor 8 inhibitor on emicizumab prophylaxis in a previously tolerized patient

ISTH Academy, Faculty / Presenters, 401406

HTRS2023.P2.13 Off-target toxicity of CART cell therapy in murine hemophilia A with inhibitors

ISTH Academy, Faculty / Presenters, 401407

HTRS2023.P2.14 A case of thrombosis in acquired hemophilia A

ISTH Academy, Faculty / Presenters, 401408

HTRS2023.P2.15 Treatment burden, patient preference, and health-related quality of life in patients with hemophilia A or B with inhibitors on concizumab prophylaxis: results from the phase 3 explorer7 study

ISTH Academy, Faculty / Presenters, 401409

HTRS2023.P2.16 Prevalence of iron deficiency in patients with inherited bleeding disorders

ISTH Academy, Faculty / Presenters, 401410

HTRS2023.P2.18 Pediatric persons with hemophilia A on EHL-FVIII or emicizumab prophylaxis require iron therapy despite low annualized bleeding rate

ISTH Academy, Faculty / Presenters, 401411

HTRS2023.P2.19 Treatment burden and unmet needs in hemophilia patients with inhibitors: results from a real-world observational study in the United States

ISTH Academy, Faculty / Presenters, 401412

HTRS2023.P2.20 Common documentation errors in the electronic health records of persons with hemophilia B

ISTH Academy, Faculty / Presenters, 401413

HTRS2023.P2.22 Evaluating the effectiveness and safety of damoctocog alfa pegol prophylaxis in hemophilia A patients with a history of factor VIII inhibitors from the real-world HEM-POWR study

ISTH Academy, Faculty / Presenters, 401414

HTRS2023.P3.1 Iron deficiency in a large pediatric comprehensive bleeding disorders clinic: current screening practice and iron deficiency prevalence

ISTH Academy, Faculty / Presenters, 401415

HTRS2023.P3.2 Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: post hoc analyses from the phase 3 ENVISION study through month 36

ISTH Academy, Faculty / Presenters, 401416

HTRS2023.P3.3 Using anti-Xa monitoring to manage anticoagulation for mechanical heart valves during pregnancy

ISTH Academy, Faculty / Presenters, 401417

HTRS2023.P3.4 EAGeR (Empower Adolescent Girls): a multidisciplinary approach to iron deficiency anemia related to heavy menstrual bleeding

ISTH Academy, Faculty / Presenters, 401418

HTRS2023.P3.5 Screening for abnormal uterine bleeding in adolescents presenting to primary care clinics

ISTH Academy, Faculty / Presenters, 401419

HTRS2023.P3.6 Correlation of non-invasive hemoglobin measurement with bleeding during cesarean delivery: the PPHgb study

ISTH Academy, Faculty / Presenters, 401420

HTRS2023.P3.7 Descriptive analysis of a pediatric anticoagulation stewardship initiative to improve anticoagulation safety: a quality improvement project

ISTH Academy, Faculty / Presenters, 401421

HTRS2023.P4.1 Effect of heparin induced thrombocytopenia on outcomes of pulmonary embolism: a nationwide inpatient sample study

ISTH Academy, Faculty / Presenters, 401422

HTRS2023.P4.2 Improving judicious use of heparin induced thrombocytopenia laboratory testing using a clinician decision support tool

ISTH Academy, Faculty / Presenters, 401423

HTRS2023.P4.3 Identifying barriers and facilitators to inform implementation strategies for venous thromboembolism prevention in oncology practice using the Implementation Research Logic Model

ISTH Academy, Faculty / Presenters, 401424

HTRS2023.P4.4 DOAC compared with warfarin for VTE in underweight patients: a retrospective cohort study conducted through the VENUS Network

ISTH Academy, Faculty / Presenters, 401425

HTRS2023.P4.7 Outcomes of pulmonary embolism in patients with autoimmune hemolytic anemia: a National Inpatient Sample (NIS) study

ISTH Academy, Faculty / Presenters, 401426

HTRS2023.P4.8 Pediatric patients diagnosed with a pulmonary embolism are more likely to be diagnosed with dyspnea three or more months after diagnosis: a population-based analysis

ISTH Academy, Faculty / Presenters, 401427

HTRS2023.P4.9 Inflammation leads to short-term GAS6 elevation followed by longer-term MERTK increase, but does not influence protein S Levels, in murine plasma

ISTH Academy, Faculty / Presenters, 401428

HTRS2023.P4.10 Endothelial ERp46 supports tissue factor activity

ISTH Academy, Faculty / Presenters, 401429

Issue Information

ISTH Academy, Faculty / Presenters, 405586

New insight into the traditional model of the coagulation cascade and its regulation: illustrated review of a three-dimensional view

ISTH Academy, , 405587

Thromboembolism in nephrotic syndrome: controversies and uncertainties

ISTH Academy, Faculty / Presenters, 405588

Thromboembolic risk with gender-affirming hormone therapy: potential role of global coagulation and fibrinolysis assays

ISTH Academy, Alisa Wolberg, 405589

Psychometrics of the patient-reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banks

ISTH Academy, Lotte Haverman, 405590

Congenital thrombophilia in East-Asian venous thromboembolism population: a systematic review and meta-analysis

ISTH Academy, Zhi-Cheng Jing, 405592

Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19

ISTH Academy, Ze Zheng, 405593

Lipoprotein(a) and risk of cognitive impairment in Black and White Americans: the Reasons for Geographic and Racial Differences in Stroke cohort

ISTH Academy, Mary Cushman, 405594

Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach

ISTH Academy, Robert Medcalf, 405595

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand

ISTH Academy, Faculty / Presenters, 405596

Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay

ISTH Academy, Karen Vanhoorelbeke, 405597

Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank

ISTH Academy, Johanna Gebhart, 405598

Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults

ISTH Academy, Faculty / Presenters, 405599

Overuse and underuse of thromboprophylaxis in medical inpatients

ISTH Academy, , 405600

Toward non-factor therapy in hemophilia: an antithrombin insensitive Gla-domainless factor Xa as tissue factor pathway inhibitor bait

ISTH Academy, , 405601

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

ISTH Academy, Stefan Lethagen, 405602

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study

ISTH Academy, Faculty / Presenters, 405603

Role of heat shock protein 47 in platelet glycoprotein VI dimerization and signaling

ISTH Academy, , 405604

T2 mapping magnetic resonance imaging of cartilage in hemophilia

ISTH Academy, Andrea Doria, 405605

Tissue factor-heparanase complex: intracellular nonhemostatic effects

ISTH Academy, , 405606

Acute venous thromboembolism in patients with brain cancer: clinical course

ISTH Academy, Faculty / Presenters, 405607

Venous thromboembolism prophylaxis for hospitalized adult patients: a survey of US health care providers on attitudes and practices

ISTH Academy, Rushad Patell, 405608

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center

ISTH Academy, Assaf Barg, 405609

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis

ISTH Academy, Faculty / Presenters, 405610

Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial

ISTH Academy, Jeffrey Berger, 405611

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study

ISTH Academy, Suzanne Cannegieter, 405612

Anti-emicizumab antibodies do not cross-react with mim8 in vitro

ISTH Academy, Flora Peyvandi, 405613

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry

ISTH Academy, Flora Peyvandi, 405614

Citrullination of α2-antiplasmin is unlikely to contribute to enhanced plasmin generation in COVID-19 pathophysiology

ISTH Academy, Alisa Wolberg, 405615

No von Willebrand factor domains other than A1 are involved in type 2B von Willebrand disease: what the p.R924Q and p.A2178S variants teach us

ISTH Academy, Faculty / Presenters, 405616

Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature

ISTH Academy, Guy Young, 405617

Letter in response to Othman & Favaloro “Comparison of two ways of performing ristocetin-induced platelet agglutination (RIPA) mixing study for diagnosis of type 2B VWD”

ISTH Academy, François Mullier, 405618

Progestin-only contraception is first line for sickle cell disease: a comment on “Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias.”

ISTH Academy, , 405619

Reply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”

ISTH Academy, Flora Peyvandi, 405620